Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients

Ebbo, Mikaël; Grados, A.; Samson, M.; Groh, Matthieu; Loundou, Anderson; Rigolet, Aude; Terrier, Benjamin; Guillaud, Constance; Carra‐Dallière, Clarisse; Renou, F.; Pozdzik, Agnieszka; Labauge, Pierre; Palat, S.; Berthelot, Jean‐Marie; Pennaforte, Jean‐Loup; Wynckel, Alain; Lebas, Céline; Le Gouellec, N.; Quéméneur, T.; Dahan, Karine; Carbonnel, Franck; Leroux, Gaëlle; Perlat, Antoinette; Mathian, Alexis; Cacoub, P.; Hachulla, É.; Costedoat‐Chalumeau, N.; Harlé, Jean‐Robert; Schleinitz, N.

doi:10.1371/journal.pone.0183844

Public

Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients

Published in PLoS ONE • Sep 15, 2017

Authors:

Mikaël Ebbo

A. Grados

M. Samson

Abstract

OBJECTIVES: To assess efficacy and safety of rituximab (RTX) as induction therapy, maintenance of remission and treatment of relapses in a cohort of IgG4-related disease (IgG4-RD) patients. METHODS: Nationwide retrospective multicenter study of IgG4-RD patients treated with at least one course of RT...

Subject

Medicine

Rituximab

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!